You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

plerixafor

Showing 26 - 50 of 76
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma

Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • +2 more
  • leukapheresis
  • +3 more
  • Omaha, Nebraska
  • +13 more
Jan 21, 2022

Chronic Granulomatous Disease Trial in Moscow (Plerixafor, Gcsf)

Unknown status
  • Chronic Granulomatous Disease
  • Moscow, Russian Federation
    Dmitry Rogachev National Research Center of Pediatric Hematology
Sep 16, 2019

Bone Marrow Transplantation, Hematopoietic Stem Cells, Multiple Myeloma Trial in Baltimore (Neupogen, Hyperbaric oxygen therapy,

Withdrawn
  • Bone Marrow Transplantation
  • +3 more
  • Baltimore, Maryland
    University of Maryland Medical Center
Dec 9, 2019

Acute Myelogenous Leukemia Trial in Houston (Plerixafor, Clofarabine)

Terminated
Has Results
  • Acute Myelogenous Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 19, 2019

Fanconi Anemia Trial in Barcelona, Madrid (procedure, biological, other, drug)

Unknown status
  • Fanconi Anemia
  • IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)
  • +5 more
  • Barcelona, Spain
  • +1 more
Nov 23, 2020

Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma, Colorectal Cancer Metastatic Trial in Cambridge

Completed
  • Pancreatic Adenocarcinoma Metastatic
  • +2 more
  • Plerixafor
  • Cambridge, United Kingdom
    Addenbrookes Hospital
Jul 19, 2019

Multiple Myeloma Trial in Atlanta, New York (bortezomib (Velcade), cyclophosphamide, G-CSF)

Completed
Has Results
  • Multiple Myeloma
  • bortezomib (Velcade)
  • +3 more
  • Atlanta, Georgia
  • +4 more
Dec 18, 2019

Blood And Marrow Transplantation Trial in Houston (Filgrastim, Plerixafor, Apheresis Procedure)

Completed
Has Results
  • Blood And Marrow Transplantation
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Apr 1, 2019

HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma Trial in Los Angeles

Withdrawn
  • HLA-A*0201 Positive Cells Present
  • +3 more
  • 18F-FHBG
  • +10 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jul 22, 2020

Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma Trial in Stanford (radiation, drug, other)

Completed
Has Results
  • Adult Ependymoblastoma
  • +8 more
  • radiation therapy
  • +4 more
  • Stanford, California
    Stanford University, School of Medicine
Sep 27, 2018

Acute Myeloid Leukemia Trial in New York (plerixafor, decitabine)

Completed
  • Acute Myeloid Leukemia
  • New York, New York
    Weill Cornell Medical College
Jun 28, 2018

Sickle Cell Disease Without Crisis Trial in Boston (Plerixafor)

Completed
  • Sickle Cell Disease Without Crisis
  • Plerixafor
  • Boston, Massachusetts
    Boston Childrens Hospital
Jan 23, 2018

Major Sickle Cell Syndrome of Type SS or Sß Thalassemia Trial in Paris (Plerixafor)

Completed
  • Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia
  • Plerixafor
  • Paris, France
    Hôpital Necker - Enfants Malades
Dec 20, 2017

High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA) Trial in Boston (Plerixafor,

Terminated
  • High Grade Glioma: Glioblastoma (GBM)
  • +4 more
  • Plerixafor
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 15, 2017

Plasma Cell Myeloma, Multiple Myeloma Trial run by the NCI (Filgrastim, Plerixafor, Apheresis)

Completed
Has Results
  • Plasma Cell Myeloma
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Feb 6, 2018

Non-Hodgkin Lymphoma Trial in Seattle (drug, biological, procedure)

Completed
Has Results
  • Non-Hodgkin Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 28, 2017

Non-Hodgkin's Lymphoma, Multiple Myeloma Trial in Gainesville (Plerixafor, Filgrastim)

Completed
  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma
  • Gainesville, Florida
    Shands Cancer Hospital at the University of Florida
Jul 27, 2017

Multiple Myeloma, Lymphoma, Non-Hodgkin Trial in Saint Louis (XM02 Filgrastim, Filgrastim, Apheresis)

Completed
Has Results
  • Multiple Myeloma
  • Lymphoma, Non-Hodgkin
  • XM02 Filgrastim
  • +4 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 17, 2017

Leukemia, Myeloid, Acute, MDS, Lymphoma, Non-Hodgkin Trial in Saint Louis (Sargramostim, Plerixafor)

Completed
Has Results
  • Leukemia, Myeloid, Acute
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
May 3, 2017

Failure of Bone Marrow Graft Trial in Durham, Charleston (Plerixafor)

Completed
Has Results
  • Failure of Bone Marrow Graft
  • Plerixafor
  • Durham, North Carolina
  • +1 more
Mar 24, 2017

Leukemia, Myeloid, Acute Trial in Boston, St. Louis, Houston (G-CSF, Plerixafor, Mitoxantrone)

Completed
Has Results
  • Leukemia, Myeloid, Acute
  • Boston, Massachusetts
  • +2 more
Feb 14, 2017

MDS Trial in St. Louis (G-CSF, Plerixafor, Azacitidine)

Completed
  • Myelodysplastic Syndromes
  • St. Louis, Missouri
    Washington University School of Medicine
Mar 16, 2017

Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, Brain Tumors Trial in Worldwide (plerixafor)

Completed
  • Ewing's Sarcoma/Soft Tissue Sarcoma
  • +2 more
  • plerixafor
  • Gent, Belgium
  • +26 more
May 15, 2017

Transplantation, Stem Cell Trial in Overland Park (Ronacaleret 100 mg, Ronacaleret 400 mg, Plerixafor)

Completed
  • Transplantation, Stem Cell
  • Ronacaleret 100 mg
  • +2 more
  • Overland Park, Kansas
    GSK Investigational Site
Jun 6, 2017

Chronic Lymphocytic Leukemia, Lymphoma, Multiple Myeloma Trial in Boston (Plerixafor)

Terminated
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Plerixafor
  • Boston, Massachusetts
    Tufts Medical Center
May 5, 2017